November 2026 INVESTOR PRESENTATION NASDAQ: NUWE
Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 November 2026 INVESTOR PRESENTATION NASDAQ: NUWE NASDAQ: NUWE Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange A
How this was made
The 30-second read
Why it matters
The presentation provides decision-relevant operating snapshots (YTD revenue growth, gross margin improvement, and cash runway) that can influence positioning, but it is not a new earnings release or a definitive forward guidance update.
Market read
Traders may use the disclosed runway and margin trajectory to reassess near-term financing risk and growth momentum, but the lack of a new catalyst likely limits immediate repricing.
What to watch
Cash runway through Q2 2027 reduces near-term financing risk, but investors may still scrutinize whether adoption and margin expansion are sustainable and whether label expansion timelines translate into revenue acceleration.
Background
The 8-K is a Regulation FD disclosure furnishing NUWE’s November 2026 investor presentation focused on Aquadex ultrafiltration, pediatric growth, and financial runway.
Ticker impact
NUWE filed an 8-K with its November 2026 investor presentation highlighting Aquadex growth, margins, and cash runway through Q2 2027.
Likely modest upward bias as investors focus on runway and margin improvement, but reaction may be limited because this is primarily a marketing-style update rather than fresh audited results.
The filing is a Regulation FD disclosure (investor deck) with specific operating metrics (YTD revenue growth, gross margin, cash runway) but no new guidance, trial readout, or capital raise terms.
Market effects
Reinforces investor attention on ultrafiltration and cardiorenal solutions in hospital settings, but does not introduce new sector-wide regulatory or competitive shocks.
Primarily US healthcare/hospital procurement narrative; no direct regional macro linkage.
Limited, as the deck focuses on US addressable market and US revenue metrics.
Counterpoint
Deck metrics may reflect prior trends and assumptions; without new clinical endpoints, reimbursement updates, or formal guidance, the market may discount the impact.
Key entities
- companyNuwellis, Inc.
NUWE, provider of Aquadex ultrafiltration system; furnished investor presentation via 8-K Item 7.01.
- productAquadex
Clinically proven ultrafiltration system for precise fluid removal; central to the deck’s growth and margin narrative.
